stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Free cash flow
Sanofi's free cash flow for fiscal 2025 was $9.1B, up 14.7% from $8.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was $23.8B. Over the past ten years it has ranged from $6.4B (fiscal 2015) to $10.9B (fiscal 2021); the current reading is higher than 82% of that period. Sanofi ranks 1st of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $9.1B | 14.69% |
| FY2024 | $8.0B | (10.95%) |
| FY2023 | $8.9B | (13.65%) |
| FY2022 | $10.3B | (4.98%) |
| FY2021 | $10.9B | 52.33% |
| FY2020 | $7.1B | (10.83%) |
| FY2019 | $8.0B | 18.31% |
| FY2018 | $6.8B | 0.54% |
| FY2017 | $6.7B | 2.04% |
| FY2016 | $6.6B | 3.75% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $4.4B | (18.47%) |
| Jun 2026 | $5.4B | (55.61%) |
| Dec 2025 | $12.2B | 564.38% |
| Jun 2025 | $1.8B | (16.98%) |
| 19 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNY Sanofi | $23.8B |
| NVS Novartis AG compare | $14.1B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. compare | $11.8B |
| AMGN Amgen Inc. compare | $9.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| GSK GSK PLC Sponsored ADR compare | $8.8B |
| NVO Novo Nordisk A/S compare | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement